1) Satraplatin is similar to other platinum-based drugs (such as cisplatin and carboplatin) used for various cancer types but is the first of its kind to be administered orally as a capsule.
Criteria:
Any tumor, including lymphoma confirmed by histopatholgy or cytology
Normal CBC, renal and liver function and UA at first visit owner pays
Thoracic radiographs
NO steroids or NSAIDS
Therapy: Satraplatin 5 mg/m² daily (oral)
Benefit: Free drug to owner. Owner pays for initial workup and follow-up bloodwork (CBC’s – Day 14, 1,2,3,4 and 6 months) Chemistry panel-6 months, Rads- 3 & 6 months Follow up bloodwork can be performed at the RDVM and drug will be supplied as long as results are sent to VMTH
2) SPI-1620 is an endothelin B agonist and is being given to dogs with solid tumors prior to receiving chemo- therapy in an effort to improve drug delivery to tumor tissue.
Criteria:
Solid tumors accessible for blood flow measurements
Patients are NOT eligible if they have: renal insufficiency, coagulapathies, uncontrolled hypo or hypertension, respiratory disease, cardiac dysfunction or brain metastasis
CBC, chemistry panel, PT/PTT, UA, BP and chest rads first visit owner pays
Therapy: SPI-1620 given IV, overnight stay in ICU
Required visits: Day 7 (repeat SPI-1620 followed by standard chemo), and Day 14
Benefit: Study covers cost of drug, chemo, follow-up visits and $500.00 at end of study towards other therapy options or continued therapy with SPI-1620.
3) Intralesional radiopharmaceuticals for canine bone cancer treatment: In this clinical trial, we are infusing a radioisotope directly into the site of bone cancer, using a specialized bone drill device. The radioisotope preparation forms a gel within the tumor site, thus keeping the treatment localized to the bone and minimizing the chance of systemic side effects. Our goal is to provide a limb-salvage option for dogs diagnosed with early-stage bone cancer.
Criteria:
Dogs with single lesion appendicular OSA on plain rads
Neutrophil count > 3000 and platelets > 150,000
No prior chemo or Samarium treatment of OSA
CBC, Chemistry, UA, thoracic and limb rads + evaluation of tumor for suitability for procedure based on lesion size, invasiveness, and location
Therapy: Bone scan, echocardiogram, single dose of doxorubicin 10-14 days prior to anticipated brachytherapy
CT of lesion, agent infusion into tumor, patient must remain in radiation isolation until cleared for release (a minimum of 3 days and possibly > 1 week, depending upon tumor size).
Patient must have CBC’s run weekly for 2 weeks post infusion.
Third week following treatment; CBC, limb rads , chemotherapy (doxorubicin/carboplatin combination)
Patient will receive four planned cycles of chemotherapy after brachytherapy treatment.
Benefit: Cost of diagnostic evaluation and treatment is covered by the study once bloodwork and limb and thoracic radiographs suggest the patient is a suitable candidate
5) NHS-IL12-IL2 or NHS-IL12 Immunotherapy for canine melanoma
Criteria:
Histologically confirmed melanoma
Measureable disease that is accessible for serial peripheral measurements
Tumor size >2 cm and < 8 cm in the longest dimension
Favorable performance status i.e. pet is in good overall health
Primary or metastatic disease, newly diagnosed or recurrent
Informed owner consent
New patients must start study on a Monday
CBC, serum chemistry, UA, coag profile, chest rads and/or abdominal US
No chemo (including steroids) or rad tx within 3 weeks
NSAIDS only if patient has been receiving > 3 weeks
No current history of immune mediated disease and no significant concurrent illness (creatinine > 3.0, bilirubin > 2.0 or ↑ bile acids, ALT 2x upper normal limit, HCT < 25%, platelets < 50,000, any > grade 2 hematologic/biochemical abnormality
Therapy: SubQ injection of NHS-IL12-IL2 or NHS-IL12 on day 1, blood samples / body temp taken at specific intervals over three days.
Dogs must return on days 8, 15, 22 and 29 for bloodwork, FNA’s and tumor biopsy. If response is noted, therapy will continue every 28 days
Benefit: All treatment related costs are covered by study once dog is enrolled
Future Studies: A bladder cancer clinical trial is anticipated within the next 6 months, so please call for updates of our clinical trial list if you have potential cases.
Tissue and Blood Samples Needed:
1. If you diagnose prostatic carcinoma or colon cancer in any of your patients please give us a call to discuss treatment options.
2. We are developing a tissue bank for the following tumors for the Canine Comparative Oncology and Genomics Consortium (CCOGC): osteosarcoma, melanoma, hemangiosarcoma, mast cell tumor, soft tissue sarcoma, primary lung tumors and untreated lymphoma. If you are referring a case for surgery of one of these tumors and the clients would be willing to allow us to collect tumor tissue for this effort, please let the Oncology Clinical Trials Service know, as we may be able to offer a fee reduction.
3. Blood samples from any Standard Poodle with pedigree information (with or without cancer) is sought for genetic testing. Testing if free of charge and results can be made known to the owners.
4. Additionally we are collecting blood samples on purebred/registered canines that present with osteosarcoma, mast cell tumor, lymphoma, malignant melanoma and hemangiosarcoma.
Novel therapies available: Pilot investigations are being performed on dogs with primary or metastatic lung tumors using inhalant chemotherapy, and for dog with prostate tumors. Although no formal trial exists for these cases, some of the cost of care can often be subsidized at this early stage of clinical investigation.
Thank you!
